UK's MHRA orders recall of Napralief 250mg batches over missing dosage warnings
→Pharmacy supply teams must quarantine recalled Napralief batches now
Change
UK's Medicines and Healthcare products Regulatory Agency (MHRA) ordered a Class 3 recall of three Napralief 250mg batches, due to missing safety and dosage information.
Why it matters
Supply must stop for the affected batch numbers immediately. Stock must return to suppliers, not dispensed. Pack labelling omits key maximum-dose instructions for patients.
Implications
- — Pharmacy supply teams must immediately stop dispensing the recalled batches — continued supply breaches MHRA recall instructions.
- — Pharmacy inventory teams must immediately quarantine batches B51496, B51497, and B51102 — failure risks accidental patient supply from on-hand stock.
Unlock the full brief.
Implications — what this forces you to change
Who is affected — which roles and obligations are exposed
What to watch — binding deadlines and enforcement dates
Real-time alerts — delivered the moment a binding change is published
Clarify with AI — turn any brief into a decision for your role
Start free trial
No credit card · $29/month after trial · Active in seconds
Source
View on UK Government